Kaitlyn Bader

Elizabeth Buzney, MD, outlines the clinical hallmarks that separate erythropoietic protoporphyria from other photosensitivity disorders, starting with what clinicians won't see on exam.

Dermatology Times connects dermatology professionals with key skin disorder coverage, therapeutic strategies, clinical trial updates, and expert insights.

The fixed-dose adapalene 0.1% and benzoyl peroxide 2.5% topical OTC gel broadens nonprescription access to a combination topical regimen that has been used as a prescription product for more than 15 years.

Maryanne Makredes Senna, MD, reviews early-onset efficacy, favorable tolerability, and high rates of patient-reported improvement associated with extended-release oral minoxidil data.

Neal Bhatia, MD, describes a protocol spanning antihistamine pretreatment, in-room talk anesthesia, and post-procedure skin care to improve tolerability of photodynamic therapy.

Albert Chiou, MD, MBA, reviews updates presented at SID 2026 on phase 1 data showing soquelitinib activity in prior systemic therapy failures, with a well-balanced adverse event profile vs placebo.

Deborah Sarnoff, MD, president of the Skin Cancer Foundation, discusses recognizing actinic keratosis, clinical indicators for biopsy, and strategies for counseling patients on cumulative sun damage in response to AK Awareness Day.

Elizabeth Buzney, MD, discusses the key reasons erythropoietic protoporphyria is frequently misdiagnosed and the consequences of prolonged diagnostic delay.

William Posten, MD, discusses the evolution of keloid treatment and the clinical outcomes he has observed with excision followed by immediate radiation therapy.

Deborah Sarnoff, MD, president of the Skin Cancer Foundation, shares the importance of the "Hats On for AK" social media campaign designed to bring awareness to sun protection and reducing actinic keratosis risk.